Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

al sleep time (p<0.001), decreased total time awake (p<0.001) and improved sleep efficiency (calculated by the proportion of the time spent sleeping while in bed, p<0.001).

Intra-Cellular Therapies believes that ITI-007 promotes natural, restorative sleep. In particular, ITI-007 did not cause rebound insomnia during early morning hours and did not suppress rapid eye movement (REM) sleep as some hypnotic agents do. ITI-007 significantly and dose-dependently increased the percent of SWS early in the night (p=0.022 for the first quarter of the night, p=0.029 for the second quarter of the night). Late in the night, towards morning, ITI-007 increased the percent of Stage 2 sleep (p=0.048 for the third quarter of the night, p=0.004 for the fourth quarter of the night). ITI-007 did not affect total duration of REM sleep (p=0.124) and ITI-007 did not affect latency to the first episode of REM (p=0.143). As predicted by its mechanism, ITI-007 did not affect latency to persistent sleep (p=0.455). Overall, the increases in SWS and Stage 2 sleep came at the expense of decreased percent time spent awake or drowsy (Stage 1 sleep, p<0.001). This was especially reflected by the ability of ITI-007 to decrease percent time spent awake or drowsy in the fourth quarter of the night compared to placebo (p=0.002), a time when other hypnotics tend to cause rebound increases in early morning wakefulness.

PHASE II RESULTS FOR ITI-007

                                                                  Dose-
                                                                Response
                                                                  Trend
    Polysomnography                                             Analysis
    Outcome Measure      Mean Change from Baseline (min)         p-value
                                             ITI-007
                       Placebo      1 mg      5 mg     10 mg

    SWS  
'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   ISN has released its third ... publication series. With data aggregated from over ... 2013 within its online contractor management platform, ISNetworld, this ... indicator (KPI) statistics. The ... publication is available in two industry specific volumes: ...
(Date:12/17/2014)... Achim Noack has been named global ... In this position, Noack will assist Jerry Stoller, CEO ... marketing strategy and supervise global marketing management and implementation ... tremendous knowledge and experience in the crop protection industry,” ... and innovative thinking will be a great asset for ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... TSX: SHQ),the global specialty biopharmaceutical company, announces the release on,March 25, 2008, of ordinary shares ... Term Incentive Plan ("LTIP")., In accordance with the rules of the LTIP, the ... ... ...
... March 25 deCODE genetics,(Nasdaq: DCGN ) today ... deCODE,CEO Kari Stefansson,s presentation at BioCentury 2008 Future Leaders ... delivered at 1:30 PM ET / 5:30 GMT on,Thursday, ... Center,New York City. The webcast can be accessed through ...
... long is the menopausal,transition? New data suggest that it,s ... -- think. Clinicians often face challenges,determining if women will ... will last., To meet the needs of health ... have published two supplements dealing with,both the menopausal transition ...
Cached Biology Technology:Shire plc: Long Term Incentive Plan 2deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference 2Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition 2
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... But in a new disease-fighting role. Viruses that infect and ... era a century ago and in the former Soviet Union ... of the sticky "biofilms" of bacteria responsible for infections on ... the ACS journal Biomacromolecules . Marek Urban and ...
... FRANCISCO , May 8, 2013 Many people are ... treating eye conditions, but few may be aware of the ... the spotlight this month when Leonard Flom ... , M.D. (1926-2007), were inducted into the United States Patent ...
... On May 8 th JoVE will publish ... in bacteria. This new technology is a preliminary step in ... has led to more deaths than AIDS in the United ... of collaboration between Dr. Vitaly Vodyanoy at Auburn University and ...
Cached Biology News:Ophthalmologist Inventors of Human Identification Technology Inducted into National Inventors Hall of Fame 2Ophthalmologist Inventors of Human Identification Technology Inducted into National Inventors Hall of Fame 3Biosensor that detects antibiotic resistance brings us one step closer to fighting superbugs 2
... This BioSafe room is configured ... testing and chemical analysis. Panels are ... are easy to wipe down and ... Unique double-wall panel design creates strong, ...
... chemical fumes, allowing safe indoor ... filters remove most organic contaminants. ... flow speed = 100 fpm ... air speed monitor, quick-release filter/blower ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
... The Staccato Series of systems provide ... drug discovery , genomics, proteomics and drug ... three base configurations; Mini Workstation Series, Application ... Sciclone ELISA Station is a remarkably compact ...
Biology Products: